Heidelberger & Partners helps life sciences firms turn compliance into a strategic advantage. They enable strong compliance and governance, confident decisions with a practical, business-focused approach, offering IPO readiness (non-financial compliance), board governance, and interim CCO support.
Products, services, technology
Helping organisations prepare for U.S. public markets by strengthening non-financial compliance and building robust programmes. They enhance board effectiveness and governance to meet investor expectations, and provide hands-on compliance leadership to deliver results without full-time hires.
Cooperation possibilities
IPO readiness support for U.S. public markets, board and governance advisory, and interim or fractional Chief Compliance Officer services. Flexible, hands-on collaboration tailored to organisational needs.
- https://heidelbergerpartners.com/
- +41 79 266 69 74
- Send an email
- Martina Heidelberger
Some insights
We promote ethical leadership at board and executive levels, grounded in the belief that integrity drives success. In life sciences, we help navigate the balance between profit and vulnerable patients, positioning compliance as a strategic, independent asset beyond legal advisory.
A blend of global industry experience, an ability to embrace complexity and think in connected ways, and an understanding of human realities with temptations for profit and an ethical approach to patients, which are not mutually exclusive, acting with clarity and empathy in difficult situations.
Role models are employees at all levels who maintain their integrity despite pressure, competition, and career advancement. Even when success can blur ethical boundaries, they stay grounded in principles and do not compromise their values under external or internal pressure.
Results-driven, strategic and management competencies, building cross-functional partnerships, handling dilemma situations. Strong communication/negotiation in complex, fast-paced, intercultural environments.
Future: more process-oriented skills, stronger risk management incl. automation.
The Swiss biotech ecosystem could best support me by helping identify which biotech companies to engage with, providing insight into how compliance is structured, and indicating whether boards are open, educational, and receptive to governance analysis.
We would like to connect with stakeholders in commercial or near-commercial stage organizations for compliance-related work. For governance, we are open to engaging with any board that is educational in mindset, open to reflection, and receptive to governance analysis and improvement.
